Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
Public ClinicalTrials.gov record NCT00445068. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the efficacy and safety of LBH589B in adult patients with multiple myeloma who have received at least two prior therapies and are refractory to their last therapy. Patients must have received in prior therapy either bortezomib or lenalidomide
Study identification
- NCT ID
- NCT00445068
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 38 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 15, 2007
- Primary completion
- May 18, 2008
- Completion
- Dec 24, 2009
- Last update posted
- Jul 13, 2021
2007 – 2009
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| Aptium Oncology | Berkeley | California | 94704 | — |
| City of Hope | Duarte | California | 91010 | — |
| UCSF | San Francisco | California | 94143 | — |
| Stanford | Stanford | California | 94305 | — |
| Rocky Mountain Cancer Center | Denver | Colorado | 80218 | — |
| Christiana Care | Newark | Delaware | 19718 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Rush University | Chicago | Illinois | 60612 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Indiana University | Indianapolis | Indiana | 46203 | — |
| University of Iowa | Iowa City | Iowa | 52240-1515 | — |
| Dana Farber | Boston | Massachusetts | 02115 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Hackensack University | Hackensack | New Jersey | 07456 | — |
| Duke | Durham | North Carolina | 27710 | — |
| Wake Forest | Winston-Salem | North Carolina | 27157 | — |
| Metrohealth | Cleveland | Ohio | 44109 | — |
| Sarah Canon Research Center | Nashville | Tennessee | 37203 | — |
| Vanderbilt | Nashville | Tennessee | 37212 | — |
| University of Texas Southwestern | Dallas | Texas | 75390-9179 | — |
| CTRC | San Antonio | Texas | 78258 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
Recently updated Multiple Myeloma trials
Other public records listing Multiple Myeloma. Sorted by last update posted; newest first. Not a recommendation.
- NCT05201781: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel Recruiting
- NCT04722146: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma Active, not recruiting
- NCT07783607: MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma Not yet recruiting
- NCT06152575: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Recruiting
- NCT07776964: Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE) Not yet recruiting
- NCT07285239: Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00445068, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 13, 2021 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00445068 live on ClinicalTrials.gov.